Skye Bioscience, Inc.
SKYE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $103 | $19 | $8 | $21 |
| - Cash | $68 | $1 | $1 | $9 |
| + Debt | $0 | $5 | $2 | $2 |
| Enterprise Value | $35 | $22 | $9 | $14 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$25 | -$37 | -$19 | -$8 |
| % Margin | – | – | – | – |
| Net Income | -$27 | -$38 | -$19 | -$9 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.73 | -5.37 | -8.77 | -5 |
| % Growth | 86.4% | 38.8% | -75.4% | – |
| Operating Cash Flow | -$25 | -$14 | -$13 | -$6 |
| Capital Expenditures | -$2 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$27 | -$14 | -$13 | -$7 |